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Comparative studies on the eﬀects of the platinum complexes in use or in clinical trials are carried out in order to discover
diﬀerences in the neurotoxic potential and the reversibility of neurotoxicity. In this paper, we summarized the current literature
on neurotoxicity and chemoresistance of cisplatin (cisPt) and discussed our recent eﬀorts on the interference of cisPt and a new
platinum compound [Pt(O,O
 -acac)(γ-acac)(DMS)] (PtAcacDMS), with high speciﬁc reactivity with sulphur ligands instead of
nucleobases as cisPt, on some crucial events of rat postnatal cerebellum development. The acute eﬀects of drug treatments on
cell proliferation and death in the external granular layer and granule cell migration and the late eﬀects on the dendrite growth
of Purkinje cells were evaluated. Together with the demonstrated antineoplastic eﬀectiveness in vitro, compared with cisPt, data
suggest a lower neurotoxicity of PtAcacDMS, in spite of its presence in the brain that involves considerations on the blood brain
barrier permeability.
1.Introduction
Neurotoxicity of anticancer agents surely complicates treat-
ment of children with cancer. However, it must be taken
intoconsiderationthatsurvivalratesforchildrenwithcancer
have increased drastically over the past few decades though
chemotherapy in children with hematologic malignancy is
associated with elevations of the neurodegenerative marker
tau in the cerebrospinal ﬂuid, reaching levels observed in
other neurodegenerative disorders [1]. In this context, social
concerns are increasing for the eﬀects of chemical substances
on the nervous system of children.
The developing central nervous system (CNS) is much
more vulnerable to injury from toxic agents than the adult
CNS and prone to impairment [2]. In mammals, there are
very sensitive periods of CNS maturation during which the
brain regions may be diﬀerentially aﬀected by various chem-
icals [3, 4]. Moreover, as regards rat cerebellum, for instance,
it is known that its cytoarchitecture is achieved around
twenty days of life, but an insult to cell proliferation aﬀects
only some particular cell types forming in its presence [2].
Agents with this action have very diﬀerent eﬀects in mitotic
granule cells and postmitotic neurons, but the reduction
of cell number in the internal granular layer (IGL) deeply
aﬀects the dendrite growth of Purkinje neurons [5]. This
allows many neuroanatomical and functional alterations in
the cerebellum as a consequence of postnatal insults [6].
Exposure or treatment with therapeutic agents induces
a variety of functional abnormalities in the brain. Among
anticancer drugs, cisplatin (cisPt) is the most common
therapy drug (for review, see [7]). It is widely used for child-
ish malignancies as an essential component of multidrug
frontlinetherapy regimens forchildren [8]withsolid tumors
(e.g., neuroblastoma). In this regard, it is interesting to note
that recent studies have identiﬁed a large number of long-
term behavioural issues (such as depression, anxiety, and
antisocialbehavior)inpediatriconcologypatients,especially
those treated for CNS tumors [9]. The beneﬁt of cisPt is2 Chemotherapy Research and Practice
compromised by severe side eﬀects including neurotoxicity
[7], that can result in neurodegeneration and cell death
(e.g., cerebellum cell loss; [10]). In addition, one of the
major obstacles to achieving the desired responses to cisPt
treatment is resistance to therapy, for instance, through
DNA repair [7]. Unfortunately, some of the targets involved
in chemoresistance may also play normal physiological
functions, and consequently reversing resistance should be
pursued with caution to avoid potential toxicities [11]. For
these reasons, several avenues are underway to prevent or
minimize the toxicities and conserve the eﬀectiveness of the
platinum chemotherapy drugs. One strategy may be the
synthesis of new platinum compounds with diﬀerent target
from DNA and low toxicity proﬁle.
In this paper, we summarized the current literature
on neurotoxicity and chemoresistance of platinum com-
pounds and examined our recent eﬀorts on the interfer-
ence of cisPt and a new platinum compound ([Pt(O,O -
acac)(γ-acac)(DMS)])(PtAcacDMS) on some important
events of crucial stages of the postnatal cerebellum develop-
ment [12]. Particular attention was addressed to the acute
eﬀects at PD11 (postnatal day 11) of drug treatments on the
active cell proliferation in the external granular layer (EGL)
and the granule cell migration from the EGL to the IGL
and the late eﬀects at PD17 on the tree dendrite growth of
Purkinje cells and the regeneration of the EGL.
1.1. Neurotoxicity. The nervous system is frequently the site
of symptomatic toxicity of antineoplastic agents. Most com-
mon neurological complications involve acute alterations
in consciousness, seizures, cerebral strokes, paralysis, neu-
ropathies, leukoencephalopathy, and ototoxicity. In the last
years, the expanded use of older agents and the development
of new chemotherapeutic compounds had a major impact
on the improvement regarding a high-dose chemotherapy,
also in connection with stem cell transplantation regimen
[13].Thepositive resultshavefocusedincreasedattentionon
posttherapeuticeﬀectsofanticancerdrugs,butthemolecular
mechanism of chemotherapy-induced neurotoxicity has not
been completely elucidated.
Regarding the older agents, comparative studies on the
eﬀects of the platinum complexes in use or in clinical
trials [7, 14] have been carried out in order to discover
diﬀerencesinthe neurotoxic potential andthe reversibility of
neurotoxicity. CisPt is one of the most eﬀective chemother-
apeutic agents that is used in the management of a variety
of human tumors, including cancers of the ovary, testis,
bladder, lung, cervix, endometrium, and brain [15, 16].
Although a dose-limiting side eﬀect of cisPt has been known
to be nephrotoxicity, severe neurotoxic eﬀects have also
beennoted[7,17].Implicationsforclinicalneuropsychology
arising from neurological disruption associated with cisPt-
based therapy have been reported [18].
Platinumdrugsappeartoaﬀecttheaxons,myelinsheath,
neuronal cell bodies, and the glial structures of the neural
tissue [19]. At the cellular level, the chemotherapy interferes
with DNA replication and metabolic function of the neurons
[20]. Platinum-based agents have the propensity to enter the
dorsal root ganglia and peripheral nerves [21]a so p p o s e dt o
the brain [22].
In the last years, several morphological and molecular
changeshavedemonstratedthevulnerabilitytoasingleinjec-
tion of cisPt during the postnatally developing cerebellum,
including the degeneration of proliferating and postmitotic
neurons. Numerous haemorrhagic foci were found in the
whole cerebellar cortex, mainly seven days after treatment
performed at postnatal day 10 [23]. More recently, apoptotic
cell death in the EGL and concomitant alteration of migra-
tory process was clearly detected [12]. These ﬁndings may
represent factors inﬂuencing the Purkinje cell diﬀerentiation
and formation of synaptic contacts within the cerebellum
neural circuits. In the studies of the eﬀects of cisPt on neu-
rotransmitter molecules involved in the brain maturation,
we demonstrated that GABA, glutamate, and monoamines
are involved in the developmental cisPt-induced changes
of cerebellum architecture [23–26]. However, repair and
reorganization with remodelling of the cerebellar cortex
cytoarchitecture occurred in the developing cerebellum after
the acute cisPt-induced injuries. They include recover of
proliferation activity in the EGL, granule cell ectopia in the
molecular layer (ML), compartimentation of the ML linked
to reorientation of Purkinje cell dendrite branches, and
changed distribution of GABA-positive inhibitory interneu-
rons [26] and VGluT2 positive-climbing ﬁbre synaptic
contacts [27].
1.2. Chemoresistance. CisPt is a potent chemotherapic drug
and has a major impact in cancer medicine. The beneﬁt
of this drug is limited by neurotoxicity and resistance. In
general, cisPt is a multifactorial agent; in fact, its biochemical
mechanism depends on the interaction of more intercel-
lular changes [28], such as decreased intracellular drug
accumulation, rapid metabolism, or excretion, activation
of oncogenes and inactivation of tumor suppress genes,
alternations in the cell cycle and checkpoints, alternations
in apoptotic pathways, altered accumulation of drugs within
cells,increaseddetoxiﬁcationmediatedsystemofglutathione
S-transferase (GST), increased DNA repair, and insensitivity
to apoptosis [29, 30]. DNA is the primary target of platinum,
andDNArepaircanmediateamechanismofdrugresistance,
blocking apoptosis. Several factors modulate and contribute
to the increase of DNA damage repair. For example, NER,
nucleotide excision repair, is the major pathway for platinum
adduct removal and DNA repair [31]; Furuta and collabora-
tors in 2002 [32] have shown that cells deﬁcient speciﬁcally
in NER are hypersensitive of cisPt. GSH (glutathione) is
another cisPt target; cisPt resistant cells often show high
GSH levels [33]. High GST levels are correlated with cisPt
resistance in ovarian cancer cells [34] and other tumors
[35]. Another factor involved in the process of resistance
is represented by the microtubule alterations [36]; defective
formation of the endocytic recycling compartment may lead
to cisPt resistance and reduce uptake of cisPt and other
molecules [37]. Resistance has also been associated with
abnormal sorting of some lysosomal proteins, with cisPt
transporters into an exosomal pathway [38], with drug
sequestration in subcellular organelles such as melanosomes,Chemotherapy Research and Practice 3
with signiﬁcantly reduced drug nuclear localization and with
increased extracellular transport of melanosomes containing
cisPt [39]. Finally, the combination of all these factors
responsible for drug resistance leads to the inhibition of
apoptosis, both in vivo and in vitro,i nd i ﬀerent types of
cancers. Apoptosis can be initiated either by activation of
death receptors on the cell surface membranes (extrinsic
pathway) or through a series of cellular events primarily
processed by mitochondria (intrinsic pathway). Defects in
apoptosis can result in the expansion of a population
of neoplastic cells. The molecular changes, that have the
potential to cause apoptotic dysregulation, include activa-
tion of antiapoptotic factors (Bcl2, BclXL, Bﬂ1/A1, etc.),
inactivation of proapoptotic eﬀectors (p53, p53 pathway),
and/or reinforcement of survival signals (Survivin, FLIP, NF-
κB, etc.). Recently, it has been shown that cisPt induces
apoptosis by intrinsic pattern in neuroblastoma rat cells
[36], with increased permeability membrane, decreased
expression of Bcl2, and Bax translocation into mitochondria
[40]. About drug resistance, the mitochondrial membrane
undergoes permeability changes [41]; there is an increase
of Bcl2 antiapoptotic factor [42]. There are evidences that
drug resistance results in induction of cell death through
autophagic pathway [43]. Autophagy is a type of cellular
catabolic degradation response to nutrient starvation or
metabolic stress; it has important roles in developing tissues
andinthecontrolofneoplasticpotential.Recently,Chenand
Debnath [44] have demonstrated that autophagy represents
an important survival mechanism for cancer cells during
anticancer therapies. High levels of autophagy, observed in
tumor cells after anticancer treatment, are commonly an
adaptive response that enables tumor cells to survive the
therapeutic insult and then to develop drug resistance [45].
Santin and collaborators [41] show that cisPt is able to
activate this mechanism to induce drug resistance.
Muscella and collaborators show that new compounds of
platinumPtAcacDMSmayinducecelldeathwithoutbinding
DNA [46]. This mechanism of action could allow us to
overcome toxicity and drug-resistance phenomena,s and it
may represent a new therapeutic treatment against tumor.
1.3. The New Complex of Platinum. Current researches have
shown insight into the mechanisms of nerve damages caused
by platinum agents [47, 48]. Apoptosis has been observed
in the neurons of dorsal root ganglion following cisPt
treatment both in vitro and in vivo [49]; it is correlated
with intracellular accumulation and increased formation of
DNA adducts. Although the mechanism of the transition
from a platinum-DNA adduct to neuronal apoptosis is not
fully understood, one proposal has suggested that the DNA
repair machinery is unable to repair the damaged DNA
[50]. It has also been proposed that the cisPt adducts may
interfere with cell metabolism [23, 51]. Among the strategies
to overcome toxicity and resistance problems, related to the
clinical use of cisPt, it should be mentioned out the synthesis
of new platinum compounds with diﬀerent target from DNA
and low toxicity proﬁle. Interesting biological properties
have been shown by a class of new platinum complexes
containing acetylacetonate (Acac) and sulfur ligands such
as dimethylsulphoxide (DMSO) or dimethylsulphide (DMS)
in the platinum coordination sphere [52]. In particular,
the complex PtAcacDMS containing two Acac (one O,O -
chelate, one sigma linked by methine in gamma position)
and dimethylsulphide (DMS) in the metal coordination
sphere not only was able to induce apoptosis in endome-
trial cancer cells (HeLa), with activity up to about 100
times higher than that of cisPt, but also showed high
cytotoxicity in cisPt resistant MCF-7 breast cancer cells
[46, 53].
The cytotoxicity of the new compound PtAcacDMS is
related only to its intracellular accumulation [46, 53]. The
newcomplex,aswellasitsspeciﬁcbiologicalactivity,showed
an interesting and selective chemical reactivity against
nucleophiles with diﬀerent HSAB (Hard-Soft-Acid-Base)
character, even in the case of biological molecules such as
nucleic acid bases (guanosine, 5 -GMP) and sulphur amino
acids (methionine) [53]. The low reactivity with nucleobases
and the speciﬁc reactivity with sulphur ligands suggest that
the cellular targets could be aminoacid residues in proteins
and enzymes involved in apoptotic induction. Moreover,
mutagenic tests (Salmonella his-reversion test, Ames’ Test, a
standard reverse mutation assay on the mutagenic capability
of the complexes) were performed on PtAacDMS using cisPt
as a positive control. Interestingly, whereas cisPt exhibited
the well-known mutagenic activity, the new complex did not
show thepresenceofrevertantcolonies, thusconﬁrming that
the biological activity of the new Pt(II) complex is related
to the reaction with nongenomic biological targets [54].
These results, together with a study on intracellular signal
transduction, triggered by the Pt(II) complex, indicate that
DNA is not the main target for this complex, characterized
bylowreactivitywithnucleobasesandspeciﬁcreactivitywith
sulphur ligands.
2. ExperimentalSchedule for the Treatment
withPlatinumCompounds
Ten-day-old Wistar rats were given a single subcutaneous
injection in the nape of the neck at a dose of 5μg/g b.w.
(corresponding to the therapeutic dose suggested by Boden-
ner et al. [55]) or 10μg/g b.w. [56]o fc i s P t( 0 . 5 m g / m L ;
Teva Pharma, Italy) or the new compound PtAcacDMS. The
chemical structure [52, 54] of the complex PtAcacDMS is as
follows.
Throughout the experiment, the rats were kept in an
artiﬁcial12hlight:12hdarkcycleandprovidedratchowand
tap water ad libitum.
One day (PD11) and 7 days (PD17) after drug admin-
istration, treated and untreated control rats of the same
age were deeply anesthetized with an intraperitoneal injec-
tion of 35% chloral hydrate (100μL/100g b.w.; Sigma, St.
Louis, MO, USA). The brains were quickly removed, ﬁxed
in Carnoy’s solution (6 absolute ethanol: 3 chloroform:
1 glacial acetic acid) for 48h, then placed in absolute
ethanol and in acetone, and embedded in Paraplast X-tra
(Sigma). Paraplast-embedded sections of cerebellar vermis
were obtained in the sagittal plane.4 Chemotherapy Research and Practice
All experiments were performed according to the guide-
lines for care and use of laboratory animals as published by
the Italian Ministry of Health (DDL 116/92). All eﬀorts were
made to minimize the number of animals used and their
suﬀering.
2.1. Light Microscopy Immunohistochemistry. Slides with
Paraplast-embedded sections were dewaxed in xylene, rehy-
dratedinadecreasingethanolseries,rinsedindistilledwater,
and immunostained as described below.
2.1.1. Bax, Bcl2, and GAD67 Immunoreactions. The endoge-
nous peroxidases were suppressed by incubation of sections
with 3% H2O2 in 10% methanol in phosphate-buﬀered
saline (PBS; Sigma, St. Louis, MO) for 7min. Subsequently,
the sections were incubated for 20min in normal serum at
room temperature in order to block nonspeciﬁc antigen-
binding sites. Localization of Bax, Bcl2, and GAD67 (Glu-
tamic Acid Decarboxylase) was achieved by applying on
brain sections, respectively, a rabbit polyclonal anti-Bax
(1:30; Santa Cruz Biotechnology, Santa Cruz, CA), a rabbit
polyclonal anti-Bcl2 (1:20; Santa Cruz Biotechnology, Santa
Cruz, CA), and a rabbit monoclonal anti-GAD67 (1:200;
SantaCruzBiotechnology, SantaCruz,CA)inPBSovernight
in a dark moist chamber. Thereafter, the sections were
sequentially incubated with biotinylated secondary antibod-
ies (1:200; Vector Laboratories, Burlingame, CA, USA) for
30min and horseradish peroxidase conjugated avidin-biotin
complex (Vector Laboratories, Burlingame, CA) for 30min
at room temperature. Then, 0.05% 3,3 -diaminobenzidine
tetrahydrochloride (DAB; Sigma, St. Louis, MO) with 0.01%
H2O2 in Tris-HCl buﬀer (0.05M, pH 7.6) was used as a
chromogen. After each reaction step, sections were washed
thoroughly in PBS (two changes of 5min each). Sections
were dehydrated in ethanol, cleared in xylene, and mounted
in Eukitt (Kindler, Freiburg, Germany). The slides were
observedwithanOlympusBX51microscope,andtheimages
were recorded with an Olympus Camedia C-5050 digital
camera and stored on a PC. Corrections to brightness and
contrast, as well as the conversion of colour images to gray-
scaleimages,weremadewithPaintShopPro7(JascSoftware
Inc).
For control staining, some sections were incubated with
PBS instead of the primary antibody. No immunoreactivity
was present in this condition.
2.2. Fluorescence Microscopy Immunohistochemistry
2.2.1. Calbindin. The immunoreaction was performed
overnight at room temperature using a primary mouse
monoclonal antibody anti-CB (1:5000, Swant, Bellinzona,
Switzerland) diluted in PBS. Sections were washed in PBS
and incubated with the secondary antibodies Alexa-Fluor
488 goat antimouse (1:100, Molecular Probes, Space, Milan,
Italy) in PBS for 1h. After washing in PBS, the nuclei
were counterstained with 0.1μg/mL Hoechst 33258 for
6min, and coverslips were lastly mounted in a drop of
Mowiol (Calbiochem, San Diego, CA, USA). The slides
were viewed by ﬂuorescence microscopy with an Olympus
BX51 equipped with a 100W mercury lamp used under
the following conditions: 330–385nm excitation ﬁlter (excf),
400-nm dichroic mirror (dm), and 420-nm barrier ﬁlter
(bf), for Hoechst 33258 and 450–480nm excf, 500nm dm,
and 515nm bf for Alexa 488. Images were recorded with
an Olympus Camedia C-5050 digital camera and stored
on a PC. Images were optimized for color, brightness, and
contrast by using Paint Shop Pro 7 software (Jasc Software
Inc).
For control staining, some sections were incubated with
PBS instead of the primary antibodies. No immunoreactivity
was present in these sections.
2.3. TUNEL Histochemical Reaction. The reaction was per-
formed using a TdT-mediated dUTP nick end-labelling kit
(Roche, Penzberg, Germany).
T h es e c t i o n sw e r ed e w a x e di nx y l e n e ,r e h y d r a t e di n
a decreasing ethanol series, rinsed in PBS (Sigma), and
incubated with a permeabilization solution (0.1% Triton
X-100, 0.1% sodium citrate in PBS) for 8min at room
temperature. After rinsing two times in PBS, slides were
incubated with 50μl of TUNEL mixture conjugated with
FITC (5μL terminal deoxynucleotidyl transferase solution
and 45μL label solution) according to the manufacturer’s
instructions for 3h at 37◦C. The sections were rinsed in PBS,
and the cells were counterstained with 0.1% trypan blue in
PBS. After washing with PBS, the nuclei were counterstained
with 0.1μg/mL Hoechst 33258 for 5min, and coverslips were
mounted in a drop of Mowiol (Calbiochem, San Diego, CA,
USA).
The slides were observed by ﬂuorescence microscopy
with an Olympus BX51 microscope equipped with a 100W
mercury lamp used under the following conditions: 330–385
nm excitation ﬁlter (excf), 400-nm dichroic mirror (dm),
and 420-nm barrier ﬁlter (bf), for Hoechst 33258; 450–480
nm excf, 500-nm dm, and 515-nm bf, for FITC. Images were
recorded with an Olympus Camedia C-5050 digital camera
and stored on a PC using Olympus software, for processing
and printing.
For the control staining, some sections were incubated
without enzyme solution. No reactivity was observed.
3. Results and Discussion
The observations are performed on the apical zones of VI to
VIIIcerebellarvermislobules,sincethesepartsofcerebellum
show still an active proliferation and diﬀerentiation [5]a t1 0
days of postnatal life, that is, the date we injected rats with
the platinum compounds.
3.1. Cell Proliferation, Death, and Migration. The complex
layered architecture of cerebellum, like the cerebral cortex
and hippocampus, adds cells over a long periods and cell
production creates numbers of neurons in excess of the
number actually needed [5, 57]. The overproduction is
normally followed by a wave of cell death (programmed
cell death) to establish the proper ﬁnal number of neurons
[58, 59]. As regards the postnatally developing cerebellum, a
germinative matrix (EGL) persists until the third week [5].Chemotherapy Research and Practice 5
The matrix originate the granule cells only [60]o ft h eI G L ,
after their migration through Bergmann radial glia ﬁbres. It
is worthwhile that cerebellar defects were also found to result
from a failure of Bergmann radial glia [61], that represents
a mechanical force of cerebellar foliation [62, 63] for the
achievement of the normal cerebellum architecture. The
strictrelationshipbetweenalteredproliferationanddamaged
migrationhasbeenalsodemonstratedwithX-rayirradiation
[64], MAM [64, 65], or methylmercury [66–68].
Paying attention to the programmed cell death, that has
a critical role during development and in normal cellular
homeostasis, it has been equated with apoptosis, although
nonapoptotic forms of cell death also exist, for example,
autophagy [69]. The TUNEL reaction is a known marker
for cell apoptosis, which is regulated by the prototypical
members of a large family of Bcl2-like proteins such as Bax
and Bcl2 (for review, see [70]). A major role in regulating
neuronal death in the CNS was assumed by the proapoptotic
molecule Bax, during development and after injury [71, 72].
Bcl2isanantiapoptoticproteinexpressedathighlevelduring
development of CNS and downregulated after birth; Bcl2 is
crucial in the maintenance of neuronal survival [70].
CisPt exerts its neurotoxic action on proliferating cells
leading to a dramatic death of immature granule cells of the
EGL at early developmental stages [12]. This decrease is to a
large extent attributable to induction of apoptosis. Findings
here shown (Figures 1(a)–1(o) indicate that, comparing
w i t hc o n t r o lr a t s( Figure 1(a)), cell death was higher at
PD11 with cisPt (Figures 1(d),a n d1(j) and conﬁrm that
cisPt eﬀects are dosedependent [73, 74]. On the contrary,
PtAcacDMS at both the doses (Figures 1(g),a n d1(m)) did
not alter the distribution and labelling for TUNEL reaction.
Moreover, comparing with the controls (Figures 1(b) and
1(c)) there were evident changes of Bax (Figures 1(e), 1(h),
1(k),a n d1(n)) and Bcl2 (Figures 1(f), 1(i), 1(l),a n d1(o))
immunoreactivities after platinum compound treatments in
the EGL and Purkinje cell layer. As previously reported
[74], no changes in TUNEL labelling for both the doses
of the cisPt and PtAcacDMS were found at PD17 (not
shown),diﬀerentlyfromBax(Figures2(c)and2(e))andBcl2
(Figures 2(d) and 2(f)) immunoreactivities, in respect of the
controls (Figures 2(a) and 2(b)).
In particular, at PD11, comparing with control rats
(Figures 1(b) and 1(c)), immunoreactivity for Bax in the
immature neurons of the EGL was observed after cisPt treat-
ment (Figures 1(e) and 1(k)); the high dose revealed nests
of cells that are Bax intensely labelled (Figure 1(k))a n dB c l 2
immunonegative (Figure 1(l)). After PtAcacDMS (Figures
1(h) and 1(n)), there was increased immunoreactivity for
Bax in very small cell elements ascribable to microglial-
like cells. In both the platinum compound treatments, Bax
immunoreactivity of Purkinje cells was more intense than
in controls. Conversely, the labelling for Bcl2 was lowered
after cisPt in the EGL and Purkinje cells but maintained
the steady state after PtAcacDMS at 5μg dose and increased
in the Purkinje cells at 10μg dose. Hence, diﬀerently from
cisPt, PtAcacDMS counterbalanced early the increased Bax
immunoreactivity maintaining the Bcl2 steady state of con-
trols, especially in the EGL after the single dose, or increasing
the labelling in the Purkinje cells. This balance might assure
a limited cell death in the EGL germinative layer and cell
degeneration in the Purkinje cell population. Not only the
Purkinje neurons had an almost normal diﬀerentiation (see
Section 3.2) in PtAcacDMS-treated rats, but also a delay,
followed by alteration, of the dendrite growth occurred after
cisPt.
Interesting ﬁndings were obtained at 7 days after treat-
ments, when at the high dose regeneration of EGL occurs
[74]. Two diﬀerent patterns were found: (1) after cisPt, the
recovery of EGL thickness [74] displayed higher presence
of Bax-labelled microglial-like cells (Figure 2(c))a n dB c l 2
(Figure 2(d)) labelling in the proliferating cells of the EGL,
(2). after PtAcacDMS, the intensity and distribution of
immunoreactivities were similar as in controls (Figures 2(a)
and 2(b)), both for Bax (Figure 2(e)) and Bcl2 (Figure 2(f)).
Hence, we provide evidence that, following a drastic
cell death at PD11, the EGL may regenerate after cisPt,
but the delay in the increased immunoreactivity for Bcl2
antiapoptotic protein can induce, like a cascade, altered
dendrite growth of Purkinje cells and synaptogenesis, and
then altered cytoarchitecture [26, 27].
In this study, the presence of microglial-like cells in all
the cerebellar layers merits attention. During development,
microglia contribute to the reorganization of neuronal con-
nections, although microglia have also pivotal roles during
acute and chronic neurodegeneration and are found to be
activated under several pathological conditions or neurode-
generative processes (for a review, see [75]). Microglial cells
have populated the developing CNS before the neuronal loss
occurs and are involved in the removal of cellular debris and
dead cell corpuses [76].
Massive invasion of microglia was previously described
by one of us [73] in some regions of cerebellar cortex at 10–
15 postinjection stages of 5–10μg cisPt. The invasion was
related to the presence of hemorrhagic foci and the damages
of small blood vessels [23]. Here, the labelling for Bax and
Bcl2 showed microglia-like cells in the EGL of controls
and treated rats. Platinum compounds seemed to induce an
increase of Bax proapoptosis protein, but the immunoreac-
tivityforBcl2wasunchanged.ThechangedbalanceBax/Bcl2
can lead to subsequent microglial apoptotic cell death, as
shownrecentlyafterinterferongammatreatment[77].Based
on these data, microglia apoptosis should occur at early stage
aftertreatmentwithPtAcacDMS,whileitshouldcharacterise
the late stage (PD17) after cisPt. The undergoing cell death
of microglia is diﬃcult to explain considering the role of
microglia and the fact that mainly after PtAcacDMS a low
number of TUNEL apoptotic cells were found. On the other
hand, microglia activated by ischemic insult through an
upregulation of proapoptosis proteins may increase reactive
oxygen species generation, resulting in neuronal injury [78].
The intriguing ﬁndings we have obtained are still far away
from elucidation and need further studies with speciﬁc
markers [79].
Moreover, vulnerability was not restricted to dividing
cells since glial cells (e.g., Bergmann radial glia) and
postmitotic neurons (e.g., Purkinje cells) were also directly
damaged by this drug as noted in literature [24, 26, 80–82].6 Chemotherapy Research and Practice
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Figure1:CelldeathanddamageofproliferatinganddiﬀerentiatingcellsatPD11.TUNELreaction,BaxandBcl2immunoreactions.Treatment
with dose of 5μg/g b.w. At PD11, in comparison with control rats (a)–(c), TUNEL positive dying cells increase in the EGL after cisPt (d) as
well as Bax immunopositivity (e), especially in nests of cells (e, insert: arrow), while Bcl2 labelling decreases (f); in the Purkinje cell bodies,
the immunopositivity for Bax is high (e), while Bcl2 is lowered (f). After PtAcacDMS, there are no changes of TUNEL reactivity (g); Bax-
labelled (h) microglial-like cells (h, insert: arrows) are more distinguishable in the EGL, and Bax immunopositivity increases in the Purkinje
cells (h); the labelling for Bcl2 (i) is present in some proliferating cells of the EGL (I, insert: arrow). Treatment with dose of 10μg/g b.w. There
is a further increase of dying cells after cisPt (j) in the EGL, where nests of Bax immunopositive cells (k) and Bcl2 immunonegative cells (l
inserts: arrows) are evident; weak Bcl2 immunopositivity is shown in the EGL and in the Purkinje cells (l, insert: arrow). In comparison with
control rats (a), no changes are observed after PtAcacDMS regards TUNEL reaction (m), but several Bax immunopositive microglial-like
cells (n) are detectable in the EGL (insert: arrows) as well as some Bcl2 cells (o, insert: arrows); there is an increased Bcl2 immunoreactivity
in the Purkinje cell bodies (o). Magniﬁcation: 40x; insert: 100x.Chemotherapy Research and Practice 7
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Figure 2: Cell death and damage of proliferating and diﬀerentiating cells at PD17. Bax and Bcl2 immunoreactions. Treatment with dose of
10μg/g b.w. In comparison with control rats (a, b), an increased labelling for Bax is observed after cisPt (c). Several microglial-like cells, that
are labelled for Bax (c, insert: arrows) and Bcl2 (d, insert: arrows), are present in the EGL. The immunoreactivity for Bcl2 in the Purkinje cell
bodies (d) is intense. After treatment with PtAcacDMS, Bax (e) and Bcl2 (f) immunoreactivities are similar as in control rats; in particular,
some Bcl2 proliferating cells (f, insert: arrows) are detectable in the EGL. Magniﬁcation: 40x; insert: 100x.
The altered immunoreactivity for GFAP and morphology of
Bergmann radial glia ﬁt well with the decreased thickness of
the EGL premigratory zone at early stage. Onthe otherhand,
it cannot be excluded that cisPt exerts an indirect action
on some of the diﬀerentiating cerebellar cell populations.
In fact, it is known that there exists a close relationship
among granule cell precursors, glial ﬁbres, and growth of
Purkinje cells dendritic tree (for review, see [62]). Moreover,
it is necessary to consider that cisPt could act not only on
DNA but also on proteins [83], cytoplasmic components
(e.g., mithocondria, cytoplasmic reticulum), and metabolic
enzymes [51, 84] broadening the sphere of cell types on
which it exerts its cytotoxic action. Apart from the diﬀerent
action, PtAcacDMS did not damage the glial ﬁbres and
consequently should not alter cell migration [74].
3.2. Cell Diﬀerentiation and Synaptogenesis. The maturation
of the GABAergic Purkinje neurons occurs postnatally in the
cerebellum [5]. These neurons are the only output and act
as ﬁnal decoders of information from the cerebellar cortex.
They form synaptic contacts with parallel and climbing
ﬁbres, and the axons of ML interneurons and Golgi neurons.
Alterations of these contacts aﬀect the growth of Purkinje
cell, especially of its dendrite (for review, see [26, 27].
Degeneration of 20% of Purkinje cell population has been
described after cisPt treatment [23].
The calcium binding protein calbindin is a speciﬁc
marker of Purkinje neurons, especially for dendrite branches
[85]. In comparison with control rats (Figures 3(a) and
3(d)), the acute eﬀects of the treatment with cisPt
(Figure 3(b)) showed Purkinje cells with shorter and less
branched dendrites, but later, seven days after the treatment
(Figure 3(e)), the tree of Purkinje neurons was expanded
within the ML similarly to the controls (Figure 3(d)). These
morphological changes are included in the neuroanatomical
and functional alterations resulting from early postnatal8 Chemotherapy Research and Practice
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Figure 3: Purkinje cell dendrite growth: calbindin ﬂuorescence immunoreaction. Treatment with dose of 5 μg/g b.w. At PD11, compared to
control rats (a), the dendrite of Purkinje cells appears less extended in the cisPt-treated rats (b); some tracts of lobules lack Purkinje cells
(b). After treatment with PtAcacDMS, a less marked delay in branching is shown (c). At PD17, in respect of control features (d), the main
dendrite branches of Purkinje cells are often thicken, distorted, or crowded (e, arrows), diﬀerently from PtAcacDMS-treated rats (f) showing
a rich and ﬁne Purkinje cell branching as in controls. Treatment with dose of 10μg/g b.w. At PD17, the dendrites of Purkinje cells in cisPt-
treated rats spread within the entire ML (g), but some branches are lacking (g, arrows). After PtAcacDMS (h), the labelling evidences similar
features as in controls. Magniﬁcation: 40x.
cerebellarinsultsinrodents(forreview,see[6]).CisPteﬀects
are dose dependent; high dose (10μg/g b.w) did not further
aﬀect the growth of Purkinje neuron trees but seriously
altered their morphology; the dendrites of Purkinje cells in
cisPt-treated rats spread within the entire ML (Figure 3(g)),
but some branches are lacking.
Likewise cisPt (Figure 3(b)), PtAcacDMS slackened the
growth of Purkinje cell trees at the early stage (Figure 3(c))
aftertheinjection[74]asseenbycalbindinimmunoreaction.
Later, diﬀerently from cisPt (Figure 3(e)), the treatment with
the new platinum compound (Figure 3(f)) did not appar-
ently aﬀect the dendrite branching and extension of PurkinjeChemotherapy Research and Practice 9
neurons. Moreover, cisPt at higher dose (Figure 3(g))d e e p l y
altered Purkinje cell growth, while after PtAcacDMS treat-
ment, almost normal dendrites were observed (Figure 3(h)).
GABA is the major inhibitory neurotransmitter in the
cerebellum; it is present in Purkinje, basket, stellate, and
Golgi cells. The functional labelling of Purkinje cell diﬀeren-
tiation steps has been obtained by the enzyme of synthesis of
GABA, that is, GAD, a marker also for synaptic sites [86, 87].
Immunocytochemistry for GAD67 shows labelling of
the entire Purkinje neurons, the basket at the axon hillock
of Purkinje neurons, the inhibitory nerve terminals in the
ML and the inhibitory components (Golgi neuron axons)
of the glomeruli in the IGL. All these structures, including
the maturing basket, were visible in controls at PD11
(Figure 4(a)). CisPt treatment, at both doses, induced a
marked delay in the Purkinje cell dendrite growth and low
number of nerve terminals in the ML, (Figure 4(b) and
4(e)), while GAD67 labelling after PtAcacDMS displayed
almost normal patterns (Figure 4(c) and 4(f)), except for
the presence of axonal swellings in the form of spheroids
in some Purkinje cells (Figure 4(d)). Seven days after treat-
ments, at PD17, diﬀerently from cisPt (not shown), the
GAD67 immunopositive basket at the Purkinje cell axon
hillocks was apparently normal after PtAcacDMS at low dose
(Figure 4(h)) in respect of controls (Figure 4(g)). Moreover,
comparing with the high dose of cisPt that deeply altered
the baskets and the immunopositivity of nerve terminals
in the ML (Figure 4(i)), the PtAcacDMS induced several
recurrent collaterals of ganglionic plexuses in some tracts of
convolutions (Figure 4(j)).
Agents that blocks, directly or indirectly, signalling
informationforfurtherdevelopment ofbasiccircuitsdisturb
CNS development [2]. As previously reported, a single dose
of cisPt aﬀects several neural transmitters and their receptors
[24–27]. In particular, the changes of the GABA synthesis
enzyme (GAD) immunolabelling in the developing cerebel-
lum oﬀered the chance of evaluating the morphological and
functional damages in the neural cortical circuits after cisPt,
that is, Purkinje cell dendrite growth, basket structure at
the Purkinje cell axon hillock, and presence and distribution
of inhibitory synapses in the ML and IGL [23]. The new
platinum compound induces few alterations of the GABA
inhibitory cerebellum circuits.
3.3. Brain-Blood Barrier. The developing brain is charac-
terised by the absence or incomplete Brain-Blood Barrier
(BBB). The development of BBB is a gradual process
beginning in utero terminating around 21 days after birth
in the rat [88]. Thus, some toxic agents that never enter the
mature brain enter the developing brain freely. In the mature
brain,platinum-basedagentshavethepropensitytoenterthe
dorsal root ganglia and peripheral nerves [21] but not the
brain, due to poor penetration through BBB.
In our studies, we demonstrated the ability both of cisPt
and PtAcacDMS to reach the developing brain tissue once
injected [74]. Interestingly, the brain platinum content after
PtAcacDMS administration was up to 4-fold higher than
after cisPt. This might mean that the novel Pt complex
is less bound to plasma proteins than cisPt and can cross
the BBB more readily. In the developing cerebellum, when
the treatment has been performed, the BBB cannot impede
cisPt passage from the blood into the cerebral tissue. On
the other hand, studies show that the administration of
cisPt is associated with an increase in the BBB permeability
further facilitating the passage of cisPt across the barrier
[89, 90]. Neural and vascular lesions produced by this agent
are manifested as foci of hemorrhagic necrosis and edema
[89], in accordance with what we previously reported on
cerebellar cortex, where disrupted or damaged blood vessel
walls are visible in hemorrhagic areas after cisPt treatment
[91].
The presence of platinum in the brain tissue after
PtAcacDMS administration ﬁts in with data obtained from
in vitro studies on HeLa and MCF-7 cells [46, 53]. Similarly
to cisPt, cellular accumulation measurements showed that
theaccumulationofnovelPtcompoundislinearlycorrelated
with the drug concentration. On the other hand, the kinetics
of PtAcacDMS uptake is diﬀerent from cisPt. PtAcacDMS
concentration in the cells increases rapidly, and its cellular
accumulationinHeLaandMCF-7cellsis,respectively,about
6 and 10 times higher than that of cisPt [46, 53]. Since it is
known that the cytostatic eﬀect is closely associated with the
accumulation of platinum in the cell, this could represent an
advantage for PtAcacDMS in-so-far as it would permit to use
lower doses of this Pt complex reducing, at the same time,
the risk of side eﬀects and drug resistance.
3.4. Recovery and Remodelling. Animal and human studies
in the last two decades have demonstrated that plasticity
reorganization occurs in the mammalian nervous system
in response to peripheral and central injuries. The extent
of plasticity changes is usually greater in the developing
brain than in the adult brain although the adult brain is
still capable of a considerable degree of reorganization (for
review, see [92]).
Recovery of proliferating activity has been reported after
treatment with cytostatic drug [80], including cisPt [12]a t
late stages from injection. The regenerative capabilities of
the EGL in the developing cerebellum [5] replaces partially
cellloss,butremodellingeventsresultinginneuroanatomical
and functional alterations are often required (for review,
see [6]).
In our schedule of cisPt treatment, we have reported
both recovery of the neurogenetic processes in the EGL
starting from a week after treatment and the persistence of
alterations in Bergmann radial glia persisted [12], leading to
ectopia of granule cells [12, 26]. This event has been largely
described in the morphological alterations induced by X-ray
irradiation during cerebellar histogenesis [93, 94]; ectopia of
granulecellsisconsideredaconsequenceoflateneurogenetic
inputs, and it is produced when the late descending granule
cells stopped in the ML [93] .T h ee c t o p i ao fg r a n u l ec e l l s
has deep consequences on proper development of cerebellar
cortex cytoarchitecture (for review, see [6]). We provide
evidence that remodelling of Purkinje cell dendrites, with
reorientation of the main dendrite branches, and changes
in the inhibitory control of compartments of Purkinje
cell dendrites, occurs starting from a week after cisPt10 Chemotherapy Research and Practice
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Figure 4: Purkinje cell diﬀerentiation and synaptogenesis: GAD67 immunoreaction. Treatment with dose of 5 μg/g b.w. At PD11 (a)–(d), in
control rats (a), GAD67 labelling is shown in the entire Purkinje neurons and the dot-like nerve terminals in the ML, and the inhibitory
components (Golgi neuron axons) of the glomeruli in the IGL. After cisPt treatment, a marked delay in the Purkinje cell dendrite growth
and a low number of punctuate nerve terminals in the ML are observed (b). The GAD67 labelling after PtAcacDMS displays almost normal
patterns (c), except for presence of axonal swellings in the form of spheroids in some Purkinje cells (d, arrow). At PD17 (g, h), seven days
after treatments, diﬀerently from cisPt (not shown), the GAD67 immunopositive baskets at the Purkinje cell axon hillock (arrows) are
apparently normal (as in controls, g) after PtAcacDMS at low dose (h). Treatment with dose of 10μg/g b.w. At PD11 (e, f), the Purkinje
cell diﬀerentiation is further delayed after cisPt (e), diﬀerently from that observed in PtAcacDMS rats (f). At PD17 (i, j), deeply altered
baskets and lack of immunopositive nerve terminals in the ML are observed after cisPt (i); the treatment with PtAcacDMS induces several
recurrent collaterals of ganglionic plexuses in some tracts of convolutions, but dot-like immunopositive terminals are present in the ML (j).
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injection [26]; moreover, the elimination phase of climbing
ﬁbre synapses during Purkinje cell diﬀerentiation and the
formation/competition of parallel and climbing ﬁbres in the
soma and the deep dendrite branches of Purkinje cells was
altered or delayed [27].
Thestudiescarried outsofarshow thatafterPtAcacDMS
treatment, no early apparent signs of reorganization in
the cerebellar cortex architecture were found, at least for
the markers studied till now. But, this is not a paradox
since cell death and recovery, and their markers, of the
proliferative activity were not drastically changed compared
with controls; Purkinje cell dendrites displayed a less altered
morphology, also at the higher dose (10μg/mg b.w.). Never-
theless,onedayafterinjection,thepresenceofsomePurkinje
cells with axonal swellings in the form of spheroids has been
observed; these alterations have been also described after
intoxication with acrylamide [95]. These early alterations
in the developing cerebellum, together with hypertrophy of
ganglionic plexuses, observed later also after cisPt, may be
considered signs of compensatory reaction to Purkinje cell
axon injury and degeneration that means to start a program
of axon regeneration in a permissive environment [96, 97].
This ﬁnding may be indicative of the presence of injured cells
within the Purkinje population. Researches are in progress to
evaluatepossiblepersistentdamagesandrecoverywithinthis
neuron population and cerebellar cortex architecture.
4. Conclusions
PtAcacDMS induces less severe changes than cisPt on
fundamental events of normal CNS development, that is,
no signiﬁcant apoptotic events, less altered granule cell
migration, and Purkinje cell dendrite growth, pointing to
a reduced neurotoxicity of this Pt complex. Moreover, the
balance between Bcl2/Bax proteins favours the PtAcacDMS
treated rats assuring normal features. The mild cytotoxic
eﬀects could be attributable to diﬀerent subcellular targets
o ft h i sc o m p o u n da sw e l la st oag r e a t e re ﬃciency of cell
repair system to recognize the drug-target adducts and to
repair them. Together with the demonstrated antineoplastic
eﬀectiveness in vitro [46, 53], these results suggest that
PtAcacDMSmaybeapotentialalternativetocisPtindicating,
at the same time, that the choice of cisPt analogues with
new subcellular targets could be a strategy to prevent
neurotoxicity induced by platinum compounds. Moreover,
theabilityofPtAcacDMStoexertacytotoxicactiononMCF-
7 breast cancer cells, a human cell line relatively resistant to
cisPt, could further promote the use of this Pt complex in
cancer treatment to overcome resistance to chemotherapy, at
least in case of drug resistance induced by mutations in the
intrinsic apoptotic pathway.
Abbreviations
BBB: Blood-Brain Barrier
cisPt: Cisplatin
CNS: Central nervous system
EGL: External granular layer
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ML: Molecular layer
PD: Postnatal day
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PtAcacDMS: [Pt(O,O -acac)(γ-acac)(DMS)].
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